Why in news?
India's Central Drugs Standard Control Organization issued a circular on 21 September warning against indiscriminate painkiller and antibiotic use. It calls on patients, prescribers, pharmacies, hospitals and state regulators to prevent avoidable kidney injury and other harms. The warning particularly concerns non-steroidal anti-inflammatory drugs, a group used to reduce pain and inflammation, and inappropriate antibiotic treatment. The circular reiterates medical supervision and compliance with existing prescription and labelling requirements. It is not a newly notified blanket withdrawal of every painkiller from the market. Its practical concern is whether medicines are clinically needed, appropriately selected and supplied according to the rules governing them.
Which authority is acting?
The Central Drugs Standard Control Organization, or CDSCO, performs central regulatory functions under India's drugs legislation. It operates within the Directorate General of Health Services under the Ministry of Health and Family Welfare. Its responsibilities include new-drug and clinical-trial approvals, import regulation and specified licensing functions. It does not replace every state-level drug-control authority. The regulatory system distributes responsibilities, so a national circular must translate into action by several institutions.
The circular is signed by the Drugs Controller General of India, Rajeev Singh Raghuvanshi. It addresses both the public and the professionals involved in prescribing, dispensing and monitoring medicines. State and union-territory authorities are asked to promote awareness and ensure compliance with applicable law. Hospitals are advised to strengthen prescription review and patient counselling. This is a chain of responsibility, not a message aimed only at people buying tablets without advice.
Why common painkillers can affect the kidneys
Non-steroidal anti-inflammatory drugs, or NSAIDs, reduce pain and inflammation through their effects on chemical pathways in the body. Some of those pathways also help maintain blood flow within the kidneys. Interfering with them can become harmful when a person's kidneys are already vulnerable. Risk can rise with dehydration, existing kidney disease, certain other illnesses or interacting medicines. A product being familiar or widely used does not make its risks identical for every patient.
The United States National Institute of Diabetes and Digestive and Kidney Diseases explains that NSAIDs can cause acute kidney injury during dehydration. Prolonged use can also damage kidneys in susceptible circumstances. Acute injury develops over a relatively short period; chronic kidney disease involves persistent damage or loss of function. The circular is concerned with avoiding preventable harm across this spectrum. It does not establish that every brief, appropriately prescribed course causes chronic kidney disease.
For prescribers, the circular recommends considering the patient's condition, age, other medicines and relevant risk factors. It favours the lowest effective NSAID dose for the shortest appropriate duration, particularly in people at increased renal risk. These are prescribing principles, not instructions for readers to change treatment independently. Persistent pain or fever requires assessment rather than repeated unsupervised medicine use. Patients should discuss concerns with the clinician responsible for their care.
Antibiotics raise a different, additional problem
Antibiotics act against bacteria; they do not treat an uncomplicated viral illness simply because it causes fever or discomfort. Choosing an antibiotic requires attention to the likely organism, infection site and clinical severity. The circular also calls for appropriate investigations and consideration of local susceptibility patterns where relevant. These patterns describe which medicines are likely to remain effective against local bacteria. They help avoid treatment choices based only on habit or availability.
Misuse can contribute to antimicrobial resistance, where microorganisms become less responsive to medicines intended to control them. It is the microorganism that becomes resistant, not a person's body becoming accustomed to treatment. Resistant infections can become harder to treat and can spread to others. This gives prescribing decisions consequences beyond one patient. Appropriate treatment still remains essential when bacterial infection requires it; responsible use does not mean refusing necessary antibiotics.
The circular advises against sharing antibiotics or using leftover medicines for self-treatment. Healthcare professionals are asked to avoid unnecessary combinations, unsuitable selection and unnecessarily prolonged courses. Hospitals should support antimicrobial stewardship: organised efforts to improve how these medicines are selected and used. That includes reviewing prescriptions and counselling patients. The purpose is to preserve effective treatment while reducing avoidable exposure. A simple “more medicine” or “less medicine” rule cannot replace clinical judgement.
What the prescription schedules actually require
The Drugs Rules, 1945 place substances into schedules with different regulatory conditions. Rule 65 restricts retail supply of Schedule H, H1 and X drugs to a registered medical practitioner's prescription. Rule 97 prescribes relevant labelling and warning requirements. Schedule H1 also carries a separate dispensing-record requirement, with records retained for three years. These provisions existed before the September circular. The circular calls for compliance rather than creating an entirely new prescription framework.
The legal conditions depend on the substance and applicable schedule; the labels are not interchangeable categories for all medicines. Schedule G, also mentioned in the circular, concerns a medical-supervision warning. It should not be treated as identical to every retail-prescription condition under Schedule H or H1. The circular's practical directions refer to applicable rules and prescription-only products. A news headline saying all painkillers have been newly banned would therefore give readers the wrong impression.
Conclusion
The September warning links responsible prescribing with responsible dispensing and informed medicine use. Its central message is that indication, patient risk, dose and duration matter, even for familiar drugs. Existing prescription requirements remain the legal basis for restricted retail supply. Effective implementation means pharmacies observe those conditions, clinicians review risk, and patients receive clear advice. It does not mean abruptly stopping necessary prescribed treatment or assuming that all pain relief has become unlawful.